Roche Holding Ltd - Nov 2, 2021 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
10%+ Owner
Signature
/s/ Jared Cohen, as Attorney-in-Fact
Stock symbol
TRDA
Transactions as of
Nov 2, 2021
Transactions value $
$0
Form type
4
Date filed
11/4/2021, 09:45 PM
Previous filing
Oct 28, 2021
Next filing
Jan 26, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRDA Common Stock Conversion of derivative security +2.5M 2.5M Nov 2, 2021 See Footnote F1, F2
transaction TRDA Common Stock Conversion of derivative security +318K +12.75% 2.81M Nov 2, 2021 See Footnote F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRDA Series A Preferred Stock Conversion of derivative security $0 -2.5M -100% $0.00* 0 Nov 2, 2021 Common Stock 2.5M See Footnote F1, F2
transaction TRDA Series B Preferred Stock Conversion of derivative security $0 -318K -100% $0.00* 0 Nov 2, 2021 Common Stock 318K See Footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.
F2 Represents shares held by Roche Finance Ltd ("Roche Finance"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd ("Roche Holding"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 4 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4.